Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avenue TherapeuticsATXI 32 3-Year EBITDA Growth Rate is 76.80% as of Jun. 2026, which is 44% above its 10-year median of 53.20. GuruFocus rates ATXI with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Avenue Therapeutics ranks better than 95.56% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 76.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 67.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avenue Therapeutics was 76.80% per year. The lowest was -80.20% per year. And the median was 53.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Avenue Therapeutics 3-Year EBITDA Growth Rate Related Terms
ATXI vs ABPO, BBLG, SCNI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Avenue Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 76.80% mean?
Avenue Therapeutics (ATXI) has a 3-Year EBITDA Growth Rate of 76.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avenue Therapeutics and its competitors. This is 44% above median its historical median of 53.20. According to the industry distribution chart, Avenue Therapeutics ranks #50 out of 1127 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Avenue Therapeutics' 3-Year EBITDA Growth Rate too high?
Avenue Therapeutics' current 3-Year EBITDA Growth Rate of 76.80% is 44% above median its 10-year median of 53.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Avenue Therapeutics' value of 76.80% is 426% above this industry median. Based on the distribution chart, Avenue Therapeutics ranks #50 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avenue Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' 3-Year EBITDA Growth Rate compare to ABPO and BBLG?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #50 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Avenue Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Avenue Therapeutics' value of 76.80% is 426% above this benchmark. While the company's 10-year median is 53.20 vs. the industry median of 14.60, Avenue Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current 3-Year EBITDA Growth Rate of 76.80% is 426% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avenue Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current 3-Year EBITDA Growth Rate is 76.80%, which is 44% above median its own 10-year median of 53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current 3-Year EBITDA Growth Rate of 76.80%. The current 3-Year EBITDA Growth Rate is 76.80%, which is 44% above median its 10-year median of 53.20 and 426% above the Biotechnology industry median of 14.60. Avenue Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current 3-Year EBITDA Growth Rate is 76.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
32GF Score
Get the complete analysis for ATXI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
